---
layout: default
title: Bempedoic Acid
description: "Bempedoic Acid çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 29
evidence_level: L5
indication_count: 10
---

# Bempedoic Acid

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Bempedoic Acidï¼šå¾é«˜è†½å›ºé†‡åˆ°åŒåˆå­å®¶æ—æ€§é«˜è†½å›ºé†‡è¡€ç—‡

## ä¸€å¥è©±ç¸½çµ
<p class="key-answer" data-question="Bempedoic Acid å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Bempedoic acid æ˜¯ ATP æª¸æª¬é…¸è£‚è§£é…¶æŠ‘åˆ¶åŠ‘ï¼Œç”¨æ–¼é™ä½ LDL-Cï¼ŒTxGNN é æ¸¬å…¶å°åŒåˆå­å®¶æ—æ€§é«˜è†½å›ºé†‡è¡€ç—‡ (HoFH) æœ‰é¡å¤–åƒ¹å€¼ï¼Œæ­¤é æ¸¬å·²ç²æ–‡ç»å¼·åŠ›æ”¯æŒã€‚
</p>


## å¿«é€Ÿç¸½è¦½
| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | åŸç™¼æ€§é«˜è†½å›ºé†‡è¡€ç—‡ã€æ··åˆå‹è¡€è„‚ç•°å¸¸ã€å‹•è„ˆç²¥ç‹€ç¡¬åŒ–å¿ƒè¡€ç®¡ç–¾ç—…é¢¨éšªé™ä½ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | åŒåˆå­å®¶æ—æ€§é«˜è†½å›ºé†‡è¡€ç—‡ (homozygous familial hypercholesterolemia) |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.48% |
| è­‰æ“šç­‰ç´š | L3 (å¤šç¯‡æ–‡ç»æ”¯æŒï¼ŒçœŸå¯¦ä¸–ç•Œæ•¸æ“š) |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 1 |
| å»ºè­°æ±ºç­– | Go |


## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. hyperthyroidism</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.61%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content" markdown="1">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

<p class="key-answer" data-question="é€™å€‹è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰æ˜¯ä»€éº¼ï¼Ÿ">
Bempedoic acid é€éæŠ‘åˆ¶ ATP æª¸æª¬é…¸è£‚è§£é…¶ (ACL) é™ä½è†½å›ºé†‡åˆæˆï¼Œä½œç”¨ä½é»åœ¨ HMG-CoA é‚„åŸé…¶çš„ä¸Šæ¸¸ã€‚å° HoFH æ‚£è€…çš„é—œéµå„ªå‹¢ï¼š
1. **é LDL å—é«”ä¾è³´æ©Ÿåˆ¶**ï¼šHoFH æ‚£è€… LDL å—é«”åŠŸèƒ½ç¼ºææˆ–ç¼ºå¤±ï¼Œå‚³çµ± statin å’Œ PCSK9 æŠ‘åˆ¶åŠ‘æ•ˆæœå—é™
2. **èˆ‡ç¾æœ‰ç™‚æ³•å”åŒ**ï¼šå¯èˆ‡ statinã€ezetimibeã€PCSK9 æŠ‘åˆ¶åŠ‘ç­‰åˆä½µä½¿ç”¨
3. **ä¸ä¾è³´è‚Œè‚‰ä»£è¬**ï¼šä½œç‚ºå‰è—¥åƒ…åœ¨è‚è‡Ÿæ´»åŒ–ï¼Œä¸æœƒåœ¨è‚Œè‚‰ç´°èƒä¸­æ´»åŒ–ï¼Œæ¸›å°‘è‚Œè‚‰ç›¸é—œå‰¯ä½œç”¨
</p>

<div class="key-takeaway">
æ­¤é æ¸¬åŸºæ–¼è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰ï¼Œèˆ‡ç¾æœ‰è‡¨åºŠè­‰æ“šæ–¹å‘ä¸€è‡´ã€‚
</div>

### è‡¨åºŠè©¦é©—

| è©¦é©—ç·¨è™Ÿ | éšæ®µ | ç‹€æ…‹ | æ”¶æ¡ˆäººæ•¸ | ä¸»è¦ç™¼ç¾ |
|----------|------|------|----------|----------|
| - | - | - | - | (ç„¡å°ˆé–€ HoFH çš„è¨»å†Šè‡¨åºŠè©¦é©—) |

### ç›¸é—œæ–‡ç»

| PMID | å¹´ä»½ | æ¨™é¡Œ | ç›¸é—œæ€§ |
|------|------|------|--------|
| 41274797 | 2026 | Real-world evaluation of bempedoic acid use in patients with homozygous familial hypercholesterolemia | ç›´æ¥ç›¸é—œï¼šHoFH æ‚£è€…ä½¿ç”¨ bempedoic acid çš„çœŸå¯¦ä¸–ç•Œæ•¸æ“š |
| 41106315 | 2025 | Breaking barriers: Innovative therapies for managing homozygous familial hypercholesterolemia | ç¶œè¿° HoFH æ–°ç™‚æ³•ï¼ŒåŒ…å« bempedoic acid |
| 35466160 | 2022 | Advancements in the Treatment of Homozygous Familial Hypercholesterolemia | HoFH æ²»ç™‚é€²å±•ï¼ŒæåŠ bempedoic acid |
| 33766264 | 2021 | New and Emerging Therapies for Reduction of LDL-Cholesterol | LDL-C é™ä½æ–°ç™‚æ³•ï¼Œæ¶µè“‹ HoFH æ‡‰ç”¨ |
| 29449335 | 2018 | Bempedoic Acid Lowers LDL-C in LDLR-Deficient Yucatan Miniature Pigs | å‰è‡¨åºŠç ”ç©¶ï¼šåœ¨ LDL å—é«”ç¼ºé™·å‹•ç‰©æ¨¡å‹ä¸­è­‰å¯¦ç™‚æ•ˆ |

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.58%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.58%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. malignant catarrh</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.58%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.58%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. infectious bovine rhinotracheitis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.58%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.58%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. cytomegalovirus infection</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.53%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.53%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. homozygous familial hypercholesterolemia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.48%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.48%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. hyperthyroxinemia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.34%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.34%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. drug-induced osteoporosis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.21%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.21%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. multiple endocrine neoplasia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.18%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.18%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. pregnancy associated osteoporosis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.17%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.17%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š
| è¨±å¯è­‰è™Ÿ | ä¸­æ–‡å“å | åŠ‘å‹ | è¨±å¯è­‰æŒæœ‰è€… | æ•ˆæœŸ |
|----------|----------|------|--------------|------|
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬028817è™Ÿ | å¯§è„‚å¾·è†œè¡£éŒ 180æ¯«å…‹ | è†œè¡£éŒ  | å°ç£ç¬¬ä¸€ä¸‰å…± | 2029/11/05 |

## å®‰å…¨æ€§è€ƒé‡
- **Major äº¤äº’ä½œç”¨**ï¼š
  - é¡å›ºé†‡é¡ï¼šhydrocortisone, prednisone, prednisolone, methylprednisolone, dexamethasone, betamethasone, budesonide, deflazacort, fludrocortisone
  - Simvastatinï¼šå¢åŠ è‚Œç—…é¢¨éšªï¼ŒåŠ‘é‡éœ€é™åˆ¶åœ¨ 20mg
  - Levofloxacinï¼šå¢åŠ è‚Œè…±ç—…è®Šé¢¨éšª
- **Moderate äº¤äº’ä½œç”¨**ï¼š
  - Rosuvastatinï¼šå»ºè­°åŠ‘é‡ä¸è¶…é 40mg
  - å¤šç¨®å…¶ä»–è—¥ç‰©


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**Hepatic Insufficiency** ğŸŸ¡ Moderate
- Bempedoic acid has not been studied in patients with severe hepatic impairment (Child-Pugh C), therefore, caution is advised if used in these patients.  No dosage adjustment is needed in patients with mild or moderate hepatic impairment (Child-Pugh A...

**Hyperuricemia** ğŸŸ¡ Moderate
- Bempedoic acid can elevate serum uric acid.  Caution is advised in patients with a history of gout.  Assess uric acid levels periodically and monitor any signs or symptoms of hyperuricemia.

**è…è‡Ÿç–¾ç—… (Kidney Diseases)** ğŸŸ¡ Moderate
- There is limited experience with the use of bempedoic acid in patients with severe renal impairment, and the drug has not been studied in patients with end-stage renal disease (ESRD) receiving dialysis.  Caution is advised if used in these patients.

**Tendon Injuries** ğŸŸ¡ Moderate
- Bempedoic acid has been associated with an increased risk of tendon rupture or injury.  Ruptures involving the rotator cuff, biceps, or Achilles tendon have been reported.  Risk increases in patients over 60, those on corticosteroid or fluoroquinolon...

## çµè«–èˆ‡ä¸‹ä¸€æ­¥
**æ±ºç­–ï¼šGo**
**ç†ç”±ï¼š** TxGNN çš„é æ¸¬å·²ç²å¾—å¤§é‡æ–‡ç»æ”¯æŒï¼ŒåŒ…æ‹¬ 2026 å¹´æœ€æ–°ç™¼è¡¨çš„çœŸå¯¦ä¸–ç•Œæ•¸æ“šç ”ç©¶ã€‚Bempedoic acid å° HoFH çš„ç™‚æ•ˆæ©Ÿè½‰æ˜ç¢ºï¼Œä¸”å·²æœ‰å¤šç¯‡ç¶œè¿°æ–‡ç« å°‡å…¶åˆ—ç‚º HoFH æ²»ç™‚é¸é …ä¹‹ä¸€ã€‚è—¥ç‰©å·²åœ¨å°ç£ä¸Šå¸‚ï¼Œå…·å‚™ç«‹å³è‡¨åºŠæ‡‰ç”¨çš„æ¢ä»¶ã€‚
**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
1. èˆ‡å¿ƒè‡Ÿç§‘/è„‚è³ªé–€è¨ºåˆä½œï¼Œåœ¨ HoFH æ‚£è€…ä¸­é–‹å§‹ä½¿ç”¨
2. æ”¶é›†å°ç£ HoFH æ‚£è€…ä½¿ç”¨ç¶“é©—ï¼Œå»ºç«‹æœ¬åœŸæ•¸æ“š
3. è€ƒæ…®ç”³è«‹é©æ‡‰ç—‡æ“´å±•
4. æ³¨æ„èˆ‡ simvastatin çš„äº¤äº’ä½œç”¨ï¼Œé¿å…è¶…éå»ºè­°åŠ‘é‡


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Voriconazole]({{ "/drugs/voriconazole/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Pemetrexed]({{ "/drugs/pemetrexed/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Nepafenac]({{ "/drugs/nepafenac/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Amorolfine]({{ "/drugs/amorolfine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Sulfamerazine]({{ "/drugs/sulfamerazine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Bempedoic Acidè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/bempedoic_acid/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_bempedoic_acid,
  title = {Bempedoic Acidè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/bempedoic_acid/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
